PMC:6723065 / 42125-42669 JSONTXT

{"project":"2_test","denotations":[{"id":"31434341-28001447-7278370","span":{"begin":104,"end":107},"obj":"28001447"},{"id":"31434341-29869204-7278371","span":{"begin":108,"end":111},"obj":"29869204"},{"id":"31434341-24602031-7278372","span":{"begin":332,"end":335},"obj":"24602031"},{"id":"31434341-29869204-7278373","span":{"begin":539,"end":542},"obj":"29869204"}],"text":"An alternative therapeutic option for an overactive bladder is represented by Mirabegron (50 mg daily) [156,157]. This drug acts as an agonist on β3 adrenoceptors and it has no antimuscarinic action, therefore not impairing cognition. Large phase 3 Randomized Controlled Trials have assessed the efficacy of Mirabegron monotherapy [158]. No particular recommendations for patients’ age and sex have been reported, as the molecule appears very well tolerated even for long-term therapy, also due to the lack of antimuscarinic side effects [157]."}